CN100430047C - Chinese medicine composition for peridentitis and preparing method thereof - Google Patents
Chinese medicine composition for peridentitis and preparing method thereof Download PDFInfo
- Publication number
- CN100430047C CN100430047C CNB2004100127102A CN200410012710A CN100430047C CN 100430047 C CN100430047 C CN 100430047C CN B2004100127102 A CNB2004100127102 A CN B2004100127102A CN 200410012710 A CN200410012710 A CN 200410012710A CN 100430047 C CN100430047 C CN 100430047C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- fine powder
- filtrate
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 201000001245 periodontitis Diseases 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000000706 filtrate Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 21
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims 4
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 241000206501 Actaea <angiosperm> Species 0.000 abstract 2
- 244000061520 Angelica archangelica Species 0.000 abstract 2
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 229910052602 gypsum Inorganic materials 0.000 abstract 2
- 239000010440 gypsum Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000001556 precipitation Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010004542 Bezoar Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
The present invention discloses one traditional Chinese medicine composition for treating parodontitis and a preparation method thereof. The traditional Chinese medicine composition uses chinensis, cimicifuga root, gypsum, rehmannia dride rhizome, angelica and moutan bark as medicine effect components. The preparation method comprises the following steps: volatile substances are extracted from the moutan bark; the moutan bark dregs, the cimicifuga root, the gypsum, the rehmannia dride rhizome and the angelica are extracted with water; the chinensis is extracted with alcohol; the substances obtained above are prepared into the traditional Chinese medicine composition through concentration, dryness, crushing, supplementary material adding, mixing, granulation and encapsulating. The traditional Chinese medicine composition has the better functions of emptying the stomach, resisting inflammation, draining precipitation, relieving pain and inhibiting bacteria.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of periodontitis and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Periodontitis is one of modal oral pathology, is a kind of chronic infectious disease of invading gingiva, periodontal ligament and alveolar bone.With gingival swelling and pain, easily hemorrhage, periodontal pocket forms feature, periodontitis often causes patient's odontoseisis to come off, forfeiture masticatory function and have a strong impact on physical and mental health.Data shows: the sickness rate of periodontitis is up to 50%-60% among China adult.And that the danger of heart infarction takes place in the heart patient who suffers from periodontitis is higher 2～3 times than the heart patient of no periodontitis.Periodontitis and oral cavity bacterium also can cause bacterial pneumonia, and annual therefore nearly 8.3 ten thousand people are devitalized in the whole world.Because most of people are not enough to the seriousness of periodontal disease understanding, therefore, sickness rate that in recent years should disease continues to rise.Cultivate along with anaerobism behind the seventies and the progress of isolation technics, more and more evidences show that anaerobe is the dominant bacteria in the many infected specimens in oral cavity, comprising many gram negative bacterias, all can discharge endotoxin, having the various biological activity, is potential pro-inflammatory cytokine in the oral cavity.Bacillus fragilis is that clinical each section comprises most important pathogen in the department of stomatology anaerobic infection, and deep, oral cavity pus infections is normal relevant with fusiform bacilarmature.
The Chinese medicine periodontitis has a long history, and has accumulated the experience enriched, and forms complete theoretical system, has the incomparable advantage of Western medicine in some aspects.Periodontitis belongs to traditional Chinese medical science gingival atrophy category, though the traditional Chinese medical science is thought its diseased region at tooth and gum, its pathological change and gastric heat are processed and filled substantial connection, if eating and drinking without temperance or oral cavity are unclean at ordinary times, all can amass heat in stomach, gastric heat is followed through last inflammation, can cause the outbreak of primary disease, so control suitable eliminating stomach-fire.
Summary of the invention
Problem to be solved by this invention provide a kind ofly have storage, carry, taking convenience, curative effect height, Chinese medicine composition of the treatment periodontitis that dose is little, toxic and side effects is low and preparation method thereof.
Technical scheme provided by the invention is: a kind of Chinese medicine composition for the treatment of periodontitis, the method of pressing makes: with the Rhizoma Coptidis of 10～20wt%, the Rhizoma Cimicifugae of 20～35wt%, the Gypsum Fibrosum of 20～35t%, the Radix Angelicae Sinensis of 2～12wt%, the Radix Rehmanniae of 2～12wt%, the Cortex Moutan of 8～16wt% is the feedstock production fine powder, by fine powder: the weight proportion of adjuvant=1: 0.4～0.6 adds adjuvant in the fine powder, granulate, dry, sieve, promptly get Chinese medicine composition; Fine powder prepares as follows: Rhizoma Coptidis is used alcohol reflux, filters, and merging filtrate reclaims ethanol, concentrate extractum I; Cortex Moutan adopts hydrodistillation extraction volatile material altogether, filters, and gets filtrate I, and medicinal residues and surplus medicine Radix Rehmanniae, Radix Angelicae Sinensis, Gypsum Fibrosum and Rhizoma Cimicifugae decoct with water extraction, filter, filtrate II, merging filtrate I, II, concentrate extractum II, merge extractum I, II, be concentrated into thick paste, drying gets dry extract; Dry extract is broken into fine powder promptly.
The consumption of the raw material of above-mentioned preparation fine powder is preferably: the Gypsum Fibrosum of the Rhizoma Coptidis of 12～18wt%, the Rhizoma Cimicifugae of 25～30wt%, 25～30wt%, the Radix Angelicae Sinensis of 6～10wt%, the Radix Rehmanniae of 6～10wt%, the Cortex Moutan of 10～15wt%.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition: Rhizoma Coptidis is used alcohol reflux, filters, and merging filtrate reclaims ethanol, concentrate extractum I; Cortex Moutan adopts hydrodistillation extraction volatile material altogether, filters, and gets filtrate I, and medicinal residues and surplus medicine Radix Rehmanniae, Radix Angelicae Sinensis, Gypsum Fibrosum and Rhizoma Cimicifugae decoct with water extraction, filter, filtrate II, merging filtrate I, II, concentrate extractum II, merge extractum I, II, be concentrated into thick paste, drying gets dry extract; Dry extract is broken into fine powder, presses fine powder: the weight proportion of adjuvant=1: 0.4～0.6 adds adjuvant, granulates, and drying is sieved, and promptly gets required Chinese medicine composition.The Chinese medicine composition that makes can incapsulate and make capsule; Also can beat sheet and become tablet; Or pack with medicinal aluminum-plastic composite membrane.
Above-mentioned adjuvant can be selected starch or dextrin etc. for use.
It is 2～3 times that above-mentioned decocting boils number of times, and each decocting time is 1.0～1.5 hours.
The used ethanol of above-mentioned alcohol reflux is the ethanol water of 50～90% volume ratios, and extraction time is 2～3 times, and each time is 1.0～1.5 hours.
Above-mentioned Cortex Moutan extracts volatile material---paeonol with being total to hydrodistillation.
Above-mentioned granulation adopts marumerization to granulate.
The present invention has storage, carries, taking convenience, the curative effect height, and dose is little, toxic and side effects is low, and is quality controllable, and plurality of advantages such as good stability have preferably gastric emptying, antiinflammatory, rush down down, analgesia and bacteriostasis; Periodontitis had better therapeutic effect.Thereby its broad market prospect.
The pharmacodynamics of the Chinese medicine composition of treatment periodontitis of the present invention and toxicology test result of study show:
(1), main pharmacodynamics research
1, emptying test: the present invention has obvious reinforcement mice gastric emptying, and along with dosage strengthens and the effect reinforcement, with blank group ratio, significant difference (P＜0.05) is arranged.
2, gastric analysis test: three dosage groups of the present invention and detoxicating tablet of cow-bezoar group, each index of rat gastric analysis all there is not obvious influence.
3, full gastrointestinal tract ahead running test: the first grain of the present invention melena time of occurrence is faster than blank group, significant difference (P＜0.05).The detoxicating tablet of cow-bezoar group also has similar effect, but than the effect of the present invention group little (P＜0.05).Increase with dosage, discharge function of the present invention strengthens.
4, analgesic test: Dichlorodiphenyl Acetate of the present invention is pain caused to have obvious analgesic effect.
5, antiinflammatory test: each administration group of the present invention all has the effect of certain anti-mice caused by dimethylbenzene xylene ear swelling, and with blank group ratio, 1.11g/kg, 2.22g/kg (in crude drug) dosage group has significant difference (P＜0.05, P＜0.01).
6, antibacterial and bactericidal action:
1.. in vitro tests shows, the present invention pair 6 kind pathogen relevant with oral cavity infection, comprising gram-positive cocci, staphylococcus aureus, staphylococcus epidermidis, beta hemolytic streptococcus, Diplococcus pneumoniae, Gram-negative does not have brood cell's anaerobe, gums bacteroid, bacteroides fragilis and has significantly antibacterial and bactericidal action.Compare with the positive control drug detoxicating tablet of cow-bezoar, both are similar to the effect of golden Portugal bacterium, staphylococcus epidermidis, gums bacteroid, bacteroides fragilis, and Diplococcus pneumoniae the present invention slightly is better than detoxicating tablet of cow-bezoar.
2.. bacteriostatic test in the body: the present invention is to inhibitory action in the tangible body of the main pathogenic bacterium of periodontitis (Fusobacterium nucleatum, actinomyces viscosus, staphylococcus aureus) tool.The present invention of doses can effectively protect the animal that is subjected to pathogenic infection.
(2) toxicological study
1, acute toxicity test: to mouse stomach administration, LD
50Be 28.92g/kg (in crude drug), be equivalent to more than 156 times of oral recommendation consumption adult's every day, mouse peritoneal (ip) administration, LD
50Be 2.608g/kg (in crude drug), be equivalent to more than 14 times of oral recommendation consumption adult's every day.
2, long term toxicity test: around rat continuous irrigation stomach, dosage is equivalent to 60,15,3 times of clinical recommendation consumption, and all in normal range, toxic reaction is not seen to every blood parameters by histopathologic examination.
In sum, the Chinese medicine composition of treatment periodontitis of the present invention can be strengthened the gastric emptying effect of animal, quickens full gastrointestinal tract ahead running, promotes to rush down down, has obvious analgesic effect.Have significantly antibacterial and bactericidal action, to causing the important pathogenic bacteria of periodontitis---anaerobe has significantly antibacterial and bactericidal action, and does not see the effect report of domestic like product to anaerobe.Toxicity test explanation toxicity of the present invention is low.
The specific embodiment
Embodiment 1:
Get Rhizoma Coptidis 100g, Rhizoma Cimicifugae 250g, Gypsum Fibrosum 250g, Radix Angelicae Sinensis 90g, Radix Rehmanniae 90g, Cortex Moutan 150g; Rhizoma Coptidis was extracted 1.5 hours with 80% alcohol reflux twice for the first time, filtered; Extracted 1.0 hours for the second time, filter.Merging filtrate, ethanol is reclaimed in decompression (70 ℃), and concentrating under reduced pressure gets extractum (I).Cortex Moutan extracts volatile material with being total to hydrodistillation, filter, get filtrate (I), four flavors such as medicinal residues and surplus medicine Radix Rehmanniae, Rhizoma Cimicifugae, Gypsum Fibrosum, Radix Angelicae Sinensis decoct with water twice, decoct 1.5 hours for the first time, filter, decocted 1.0 hours for the second time, filter, get filtrate (II), merging filtrate (I), (II), concentrating under reduced pressure (70 ℃) gets extractum (II).Merge extractum (I), (II), concentrate thick paste, drying, dry extract.Dry extract is broken into fine powder.
Fine powder mixes with 180g starch, granulates with one-step-granulating method.Wet grain is put 60 ℃ of dryings, crosses 20 mesh sieve granulate, removes fine powder with 60 mesh sieves sieve, gets granule.Incapsulate, check gets finished product.
Embodiment 2: get Rhizoma Coptidis 200g, Rhizoma Cimicifugae 200g, Gypsum Fibrosum 200g, Radix Angelicae Sinensis 70g, Radix Rehmanniae 70g, Cortex Moutan 100g; Rhizoma Coptidis was extracted 1.5 hours with 70% alcohol reflux twice for the first time, filtered; Extracted 1.0 hours for the second time, filter.Merging filtrate, ethanol is reclaimed in decompression (70 ℃), and concentrating under reduced pressure gets extractum (I).Cortex Moutan extracts volatile material with being total to hydrodistillation, filter, get filtrate (I), four flavors such as medicinal residues and surplus medicine Radix Rehmanniae, Rhizoma Cimicifugae, Gypsum Fibrosum, Radix Angelicae Sinensis decoct with water twice, decoct 1.5 hours for the first time, filter, decocted 1.0 hours for the second time, filter, get filtrate (II), merging filtrate (I), (II), concentrating under reduced pressure (70 ℃) gets extractum (II).Merge extractum (I), (II), concentrate thick paste, drying, dry extract.Dry extract is broken into fine powder.
Fine powder mixes with 200g starch, granulates with one-step-granulating method.Wet grain is put 60 ℃ of dryings, crosses 20 mesh sieve granulate, removes fine powder with 60 mesh sieves sieve, gets granule.Incapsulate, check gets finished product.
Embodiment 3: get Rhizoma Coptidis 150g, Rhizoma Cimicifugae 250g, Gypsum Fibrosum 250g, Radix Angelicae Sinensis 75g, Radix Rehmanniae 75g, Cortex Moutan 125g; Rhizoma Coptidis was extracted 1.5 hours with 65% alcohol reflux twice for the first time, filtered; Extracted 1.0 hours for the second time, filter.Merging filtrate, ethanol is reclaimed in decompression (70 ℃), and concentrating under reduced pressure gets extractum (I).Cortex Moutan extracts volatile material with being total to hydrodistillation, filter, get filtrate (I), four flavors such as medicinal residues and surplus medicine Radix Rehmanniae, Rhizoma Cimicifugae, Gypsum Fibrosum, Radix Angelicae Sinensis decoct with water twice, decoct 1.5 hours for the first time, filter, decocted 1.0 hours for the second time, filter, get filtrate (II), merging filtrate (I), (II), concentrating under reduced pressure (70 ℃) gets extractum (II).Merge extractum (I), (II), concentrate thick paste, drying, dry extract.Dry extract is broken into fine powder.
Fine powder mixes with 190g starch, granulates with one-step-granulating method.Wet grain is put 60 ℃ of dryings, crosses 20 mesh sieve granulate, removes fine powder with 60 mesh sieves sieve, gets granule.Incapsulate, check gets finished product.
Embodiment 4: get Rhizoma Coptidis 150g, Rhizoma Cimicifugae 250g, Gypsum Fibrosum 250g, Radix Angelicae Sinensis 75g, Radix Rehmanniae 75g, Cortex Moutan 125g; Rhizoma Coptidis was extracted 1.5 hours with 65% alcohol reflux twice for the first time, filtered; Extracted 1.0 hours for the second time, filter.Merging filtrate, ethanol is reclaimed in decompression (70 ℃), and concentrating under reduced pressure gets extractum (I).Cortex Moutan extracts volatile material with being total to hydrodistillation, filter, get filtrate (I), four flavors such as medicinal residues and surplus medicine Radix Rehmanniae, Rhizoma Cimicifugae, Gypsum Fibrosum, Radix Angelicae Sinensis decoct with water twice, decoct 1.5 hours for the first time, filter, decocted 1.0 hours for the second time, filter, get filtrate (II), merging filtrate (I), (II), concentrating under reduced pressure (70 ℃) gets extractum (II).Merge extractum (I), (II), concentrate thick paste, drying, dry extract.Dry extract is broken into fine powder.
Fine powder mixes with 190g starch, granulates with one-step-granulating method.Wet grain is put 60 ℃ of dryings, crosses 20 mesh sieve granulate, removes fine powder with 60 mesh sieves sieve, gets granule.Beat sheet, check gets finished product.
Embodiment 5: get Rhizoma Coptidis 150g, Rhizoma Cimicifugae 200g, Gypsum Fibrosum 200g, Radix Angelicae Sinensis 50g, Radix Rehmanniae 50g, Cortex Moutan 120g; Rhizoma Coptidis was extracted 1.5 hours with 65% alcohol reflux twice for the first time, filtered; Extracted 1.0 hours for the second time, filter.Merging filtrate, ethanol is reclaimed in decompression (70 ℃), and concentrating under reduced pressure gets extractum (I).Cortex Moutan extracts volatile material with being total to hydrodistillation, filter, get filtrate (I), four flavors such as medicinal residues and surplus medicine Radix Rehmanniae, Rhizoma Cimicifugae, Gypsum Fibrosum, Radix Angelicae Sinensis decoct with water twice, decoct 1.5 hours for the first time, filter, decocted 1.0 hours for the second time, filter, get filtrate (II), merging filtrate (I), (II), concentrating under reduced pressure (70 ℃) gets extractum (II).Merge extractum (I), (II), concentrate thick paste, drying, dry extract.Dry extract is broken into fine powder.
Fine powder mixes with 190g starch, granulates with one-step-granulating method.Wet grain is put 60 ℃ of dryings, crosses 20 mesh sieve granulate, removes fine powder with 60 mesh sieves sieve, gets granule.Granule is packed with medicinal aluminum-plastic composite membrane, and check gets finished product.
Claims (10)
1. Chinese medicine composition for the treatment of periodontitis, the method of pressing makes: with the Rhizoma Coptidis of 10～20wt%, the Rhizoma Cimicifugae of 20～35wt%, the Gypsum Fibrosum of 20～35t%, the Radix Angelicae Sinensis of 2～12wt%, the Radix Rehmanniae of 2～12wt%, the Cortex Moutan of 8～16wt% is the feedstock production fine powder, by fine powder: the weight proportion of adjuvant=1: 0.4～0.6 adds adjuvant in the fine powder, granulate, dry, sieve, promptly get Chinese medicine composition; Fine powder prepares as follows: Rhizoma Coptidis is used alcohol reflux, filters, and merging filtrate reclaims ethanol, concentrate extractum I; Cortex Moutan adopts altogether, and hydrodistillation extracts the volatile material paeonol, filter, get filtrate I, medicinal residues and surplus medicine Radix Rehmanniae, Radix Angelicae Sinensis, Gypsum Fibrosum and Rhizoma Cimicifugae decoct with water extraction, filter, filtrate II, merging filtrate I, II, concentrate extractum II, merge extractum I, II, be concentrated into thick paste, drying gets dry extract; Dry extract is broken into fine powder promptly.
2. Chinese medicine composition according to claim 1 is characterized in that: the consumption of the raw material of above-mentioned preparation fine powder is the Rhizoma Coptidis of 12～18wt%, the Rhizoma Cimicifugae of 25～30wt%, the Gypsum Fibrosum of 25～30wt%, the Radix Angelicae Sinensis of 6～10wt%, the Radix Rehmanniae of 6～10wt%, the Cortex Moutan of 10～15wt%.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that: described adjuvant is starch or dextrin.
4. the preparation method of the described Chinese medicine composition of claim 1, it is characterized in that: Rhizoma Coptidis is used alcohol reflux, filters, and reclaims ethanol, filtrate concentrate extractum I; Cortex Moutan adopts altogether, and hydrodistillation extracts the volatile material paeonol, filter, get filtrate I, medicinal residues and surplus medicine Radix Rehmanniae, Radix Angelicae Sinensis, Gypsum Fibrosum and Rhizoma Cimicifugae decoct with water extraction, filter, filtrate II, merging filtrate I, II, concentrate extractum II, merge extractum I, II, be concentrated into thick paste, drying gets dry extract; Dry extract is broken into fine powder, and by fine powder: the weight proportion of adjuvant=1: 0.4～0.6 adds adjuvant in the fine powder, granulates, and drying is sieved, and promptly gets Chinese medicine composition.
5. according to the described preparation method of claim 4, it is characterized in that: described adjuvant is starch or dextrin.
6. according to claim 4 or 5 described preparation methoies, it is characterized in that: with the Chinese medicine composition that makes incapsulate capsule.
7. according to claim 4 or 5 described preparation methoies, it is characterized in that: the Chinese medicine composition that makes is beaten sheet get tablet.
8. according to claim 4 or 5 described preparation methoies, it is characterized in that: the Chinese medicine composition that makes is packed with medicinal aluminum-plastic composite membrane.
9. according to claim 4 or 5 described preparation methoies, it is characterized in that: it is 2～3 times that said decocting boils number of times, and each decocting time is 1.0～1.5 hours.
10. according to claim 4 or 5 described preparation methoies, it is characterized in that: the used ethanol of alcohol reflux is the ethanol water of 50～90% volume ratios, and extraction time is 2～3 times, and each time is 1.0～1.5 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100127102A CN100430047C (en) | 2004-02-10 | 2004-02-10 | Chinese medicine composition for peridentitis and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100127102A CN100430047C (en) | 2004-02-10 | 2004-02-10 | Chinese medicine composition for peridentitis and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1654056A CN1654056A (en) | 2005-08-17 |
| CN100430047C true CN100430047C (en) | 2008-11-05 |
Family
ID=34892122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100127102A Expired - Lifetime CN100430047C (en) | 2004-02-10 | 2004-02-10 | Chinese medicine composition for peridentitis and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100430047C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101123153B1 (en) | 2009-10-16 | 2012-03-19 | 안국약품 주식회사 | Composition for preventing or treating periodontal diseases containing herbal extract |
| CN101926879B (en) * | 2010-08-21 | 2011-12-21 | 荣成市科学技术情报研究所 | Chinese medicinal composition for treating odontalgia |
| CN103599243A (en) * | 2013-11-22 | 2014-02-26 | 安徽天恒药业有限公司 | Traditional Chinese medicine composition for treating gingival hemorrhage and tooth slit internal hemorrhage |
| CN104740055A (en) * | 2015-04-14 | 2015-07-01 | 李汶峰 | Traditional Chinese medicine for treating periodontitis |
| CN104784539A (en) * | 2015-04-16 | 2015-07-22 | 许培杰 | Traditional Chinese medicine for treating chronic periodontitis |
| CN105796842A (en) * | 2016-03-01 | 2016-07-27 | 孙晓东 | Traditional Chinese medicine composition for treating periodontitis and preparation method of traditional Chinese medicine composition |
| CN107518299A (en) * | 2017-08-31 | 2017-12-29 | 桐城市牯牛背农业开发有限公司 | A kind of chicken extract health care green soya bean and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336169A (en) * | 2000-07-29 | 2002-02-20 | 李斌 | Medicated toothpaste |
-
2004
- 2004-02-10 CN CNB2004100127102A patent/CN100430047C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336169A (en) * | 2000-07-29 | 2002-02-20 | 李斌 | Medicated toothpaste |
Non-Patent Citations (2)
| Title |
|---|
| 方剂学. 段富津，87-88，上海科学技术出版社. |
| 方剂学. 段富津，87-88，上海科学技术出版社. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1654056A (en) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103356443A (en) | Toothpaste | |
| CN101628085A (en) | Chinese medicinal preparation for treating gingivitis and parodontitis and preparation method thereof | |
| CN102078275A (en) | Shuanghuanglian mouthwash and preparation method thereof | |
| CN100430047C (en) | Chinese medicine composition for peridentitis and preparing method thereof | |
| CN101152509A (en) | Method of preparing traditional Chinese medicine preparation for treating chronic pharyngitis | |
| CN101406629A (en) | Buccal tablets for treating painful swelling of gingiva and preparation method thereof | |
| CN102552509A (en) | Traditional Chinese medicine combination for reducing heat and relieving cough | |
| CN106361805A (en) | Traditional Chinese medicine composition with throat clearing effect, and preparation method and preparation thereof | |
| CN1404868A (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN102198223A (en) | Medicinal preparation for treating hepatitis and cholecystitis and preparation method thereof | |
| CN1218733C (en) | Medicine for treating common cold and preparation method | |
| CN102641483B (en) | Traditional Chinese medicine composition for treating constipation | |
| CN100490857C (en) | Composition containing tazarotene | |
| CN100496558C (en) | Drug containing metronidazole | |
| CN101002854A (en) | Medicine containing clindamycin for treating acne | |
| CN100490852C (en) | Synergistic composition containing benzoyl peroxide | |
| CN102106996A (en) | Antibacterial and antiviral Chinese medicine compound preparation and preparation method thereof | |
| CN104490948A (en) | Pharmaceutical composition for treating chronic periodontitis and preparation method thereof | |
| CN100490853C (en) | Composition containing minocycline | |
| CN100490856C (en) | Chinese-western medicine composition containing spironolactone | |
| CN100490859C (en) | Medicine composition containing metronidazoline | |
| CN100490855C (en) | Chinese-western medicine composition containing azithromycin for treating acne | |
| CN100490851C (en) | Chinese-western medicine composition for treating acne | |
| CN100502909C (en) | Chinese-western medicine composition containing cimetidine for treating acne | |
| CN100496559C (en) | Drug containing ranitidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUBEI KEYI PHARMACENTIC CO., LTD. Free format text: FORMER OWNER: HUBEI LIYI MEDICINE SCI-TECH CO., LTD. Effective date: 20110607 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430061 NO. 12, SANDAO STREET, WUCHANG DISTRICT, WUHAN CITY, HUBEI PROVINCE TO: 430074 BUILDING 4, NO. 3-3, GUANDONG INDUSTRIAL PARK, DONGHU NEW TECHNOLOGY DEVELOPMENT ZONE, WUHAN CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110607 Address after: 430074, Wuhan 3-3 New Technology Development Zone, Kanto Industrial Park, No. 4, building, East Lake Patentee after: HUBEI KEYI PHARMACEUTIC Co.,Ltd. Address before: 430061 No. 12, three street, Wuchang District, Hubei, Wuhan Patentee before: HUBEI LIVSCIEN PHARM SCI & TECH CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20081105 |
|
| CX01 | Expiry of patent term |